Oslo, 31 August 2020: The board of directors of Targovax ASA (OSE:TRVX) (“Targovax” or the “Company”) has resolved to increase the share capital of the Company following the completion of a settlement period for vested restricted stock units (“RSUs”). The settlement period commenced on 21 August 2020 at 10:00 hours (CEST) and ended on 28 August 2020 at 10:00 hours (CEST).
In total were 88,272 RSUs settled, giving the RSU holders the right to subscribe for in total 88,272 shares, each with a par value of NOK 0.10, at a subscription price of NOK 0.10 per share.
1. Settlement of RSUs by primary insider
Bente-Lill Romøren, member of the board of directors and primary insider in the Company (the “Primary Insider”), settled 9,399 RSUs on 28 August 2020, which were granted at the AGM in 2017 and 2018, giving the Primary Insider the right to subscribe for an equal amount of shares in the Company at a price of NOK 0.10 per share.
The Primary Insider received the RSUs as part of her remuneration for her directorship at the board. The number of RSUs granted was calculated as the NOK amount of the RSU selected portion of the total remuneration to the board member, divided by the market price for the shares, calculated as the volume weighted average share price for the 10 trading days prior to the AGM, being NOK 23.88 per share in 2017 and NOK 14.33 per share in 2018.
2. Resolution to increase the share capital in Targovax ASA
The Company’s board of directors has on 30 August 2020, in accordance with the authorisation granted by the general meeting on 29 April 2020, resolved to increase the share capital of the Company with NOK 8,827.20 by issuance of 88,272 new shares, each with a par value of NOK 0.10, in order to facilitate the settlement of RSUs.
The share capital increase will be registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret) as soon as practically possible. The new share capital of the Company will be NOK 7,617,576.40, divided into 76,175,764 shares, each with a par value of NOK 0.10.
3. New shareholding for primary insider
Following the Primary Insider’s subscription of shares and registration of the Company’s new share capital, the Primary Insider and her close associates will hold 20,327 shares, 15,250 RSUs and nil options in the Company.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.